Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference
November 08, 2023 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
November 01, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- Successful Completion of Recruitment Driven by Strong Clinical Site Participation and Investigator Support - - Topline Data Expected in Q3 2024 - ALPHARETTA, Ga., Nov. 01, 2023 ...
Clearside Biomedical to Report Third Quarter 2023 Financial Results and Provide Corporate Update on Monday, November 13, 2023
October 31, 2023 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Clearside Biomedical Announces Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023 16:05 ET
|
Clearside Biomedical, Inc.
- Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Progressing as Planned with Nearly 30 Sites Now Open - - Proprietary Suprachoroidal Injection Platform Featured in Peer-Reviewed Publication and at ARVO,...
Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings
July 20, 2023 07:05 ET
|
Clearside Biomedical, Inc.
ALPHARETTA, Ga., July 20, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
Global Nonmydriatic Handheld Fundus Cameras Strategic Business Report 2023: Rise of AI-Powered Non-Mydriatic Handheld Devices Drives Growth
July 19, 2023 04:28 ET
|
Research and Markets
Dublin, July 19, 2023 (GLOBE NEWSWIRE) -- The "Nonmydriatic Handheld Fundus Cameras: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market...
Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
July 17, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- Evaluating CLS-AX as a Potential Twice-a-Year Therapy - - Trial Progressing with Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., July 17, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical,...
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema
July 10, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- XIPERE® is referred to as Arcatus (ARVN001) by Arctic Vision – ALPHARETTA, Ga., July 10, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company...
AI-Based Health Screening Company iHealthScreen Reaches $150K in Investments
June 26, 2023 20:25 ET
|
iHealthScreen Inc.
RICHMOND HILL, N.Y., June 26, 2023 (GLOBE NEWSWIRE) -- AI-based health screening company iHealthScreen recently announced raising $150,000 in investments on StartEngine. To date, the company has...
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
June 01, 2023 07:05 ET
|
Clearside Biomedical, Inc.
- U.S. Clinical Sites Screening Treatment-Experienced Participants with Wet AMD - - ODYSSEY Topline Results Expected in Q3 2024 - ALPHARETTA, Ga., June 01, 2023 (GLOBE NEWSWIRE) --...